Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

Articles published in
Antiviral Res
    September 2024
  1. DO TND, Abdelnabi R, Boda B, Constant S, et al
    The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
    Antiviral Res. 2024 Sep 3:105994. doi: 10.1016/j.antiviral.2024.105994.
    >> Share

    August 2024
  2. YAMASAKI M, Saso W, Yamamoto T, Sato M, et al
    Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA.
    Antiviral Res. 2024;230:105992.
    >> Share

  3. LEE P, Kim J, Oh H, Kim CU, et al
    Coronavirus Nucleocapsid-based Vaccine Provides Partial Protection against Hetero-species Coronavirus in Murine Models.
    Antiviral Res. 2024 Aug 22:105991. doi: 10.1016/j.antiviral.2024.105991.
    >> Share

  4. CONG Y, Dixit S, Perry DL, Huzella LM, et al
    Characterization of therapeutic antibodies efficacy against multiple SARS-CoV-2 variants in the hamster model.
    Antiviral Res. 2024 Aug 13:105987. doi: 10.1016/j.antiviral.2024.105987.
    >> Share

  5. KEISER PT, Zhang W, Ricca M, Wacquiez A, et al
    Amidino-Rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.
    Antiviral Res. 2024 Aug 6:105976. doi: 10.1016/j.antiviral.2024.105976.
    >> Share

    July 2024
  6. KONISHI K, Kusakabe S, Kawaguchi N, Shishido T, et al
    beta-d-N(4)-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus.
    Antiviral Res. 2024 Jul 30:105977. doi: 10.1016/j.antiviral.2024.105977.
    >> Share

  7. ROSALES R, McGovern BL, Rodriguez ML, Leiva-Rebollo R, et al
    Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2024 Jul 25:105970. doi: 10.1016/j.antiviral.2024.105970.
    >> Share

  8. RAUCH S, Costacurta F, Schoppe H, Peng JY, et al
    Highly specific SARS-CoV-2 main protease (M(pro)) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system.
    Antiviral Res. 2024 Jul 23:105969. doi: 10.1016/j.antiviral.2024.105969.
    >> Share

  9. OLIVEIRA EH, Monteleone-Cassiano AC, Tavares L, Santos JC, et al
    A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19.
    Antiviral Res. 2024;229:105968.
    >> Share

  10. YOTSUYANAGI H, Ohmagari N, Doi Y, Yamato M, et al
    Prevention of Post COVID-19 Condition by Early Treatment with Ensitrelvir in the Phase 3 SCORPIO-SR Trial.
    Antiviral Res. 2024 Jul 5:105958. doi: 10.1016/j.antiviral.2024.105958.
    >> Share

  11. JI J, Tang T, Zhu M, Wu Z, et al
    Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.
    Antiviral Res. 2024 Jul 2:105954. doi: 10.1016/j.antiviral.2024.105954.
    >> Share

    June 2024
  12. WILLIAMS N, Silva F, Schmolke M
    Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy.
    Antiviral Res. 2024 Jun 28:105951. doi: 10.1016/j.antiviral.2024.105951.
    >> Share

  13. DANIELS A, Padariya M, Fletcher S, Ball K, et al
    Molecules targeting a novel homotrimer cavity of Spike protein attenuate replication of SARS-CoV-2.
    Antiviral Res. 2024;228:105949.
    >> Share

  14. BALIGA-GIL A, Soszynska-Jozwiak M, Ruszkowska A, Szczesniak I, et al
    Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2 replication.
    Antiviral Res. 2024 Jun 24:105946. doi: 10.1016/j.antiviral.2024.105946.
    >> Share

  15. POTTER JA, Aitken A, Yang L, Hill J, et al
    HEX17(Neumifil): an intranasal respiratory biotherapeutic with broad-acting antiviral activity.
    Antiviral Res. 2024 Jun 22:105945. doi: 10.1016/j.antiviral.2024.105945.
    >> Share

  16. LIU X, Zheng M, Zhang H, Feng B, et al
    Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-CoV-2 PLpro.
    Antiviral Res. 2024 Jun 22:105944. doi: 10.1016/j.antiviral.2024.105944.
    >> Share

  17. DICKEY TH, Salinas ND, Patel P, Orr-Gonzalez S, et al
    RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.
    Antiviral Res. 2024 Jun 18:105937. doi: 10.1016/j.antiviral.2024.105937.
    >> Share

    May 2024
  18. VAN LOY B, Stevaert A, Naesens L
    The coronavirus nsp15 endoribonuclease: a puzzling protein and pertinent antiviral drug target.
    Antiviral Res. 2024 May 31:105921. doi: 10.1016/j.antiviral.2024.105921.
    >> Share

  19. LE UNP, Chang YJ, Lu CH, Chen Y, et al
    Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Antiviral Res. 2024;227:105920.
    >> Share

  20. LIANG Y, Xiao W, Peng Y, Zhang S, et al
    Development of Nanoparticle Vaccines Utilizing Designed Fc-Binding Homo-oligomers and RBD-Fc of SARS-CoV-2.
    Antiviral Res. 2024 May 21:105917. doi: 10.1016/j.antiviral.2024.105917.
    >> Share

  21. HUANG J, Wang W, Li H, Bai Y, et al
    Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
    Antiviral Res. 2024;227:105905.
    >> Share

  22. PANDEY K, Acharya A, Pal D, Jain P, et al
    SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
    Antiviral Res. 2024;227:105904.
    >> Share

  23. SALGADO-BENVINDO C, Tas A, Zevenhoven-Dobbe JC, van der Meer Y, et al
    Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile and practical infection model for antiviral research and beyond.
    Antiviral Res. 2024 May 7:105903. doi: 10.1016/j.antiviral.2024.105903.
    >> Share

    April 2024
  24. LIU X, Wang Y, Sun L, Xiao G, et al
    Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
    Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898.
    >> Share

  25. ARDUINO I, Francese R, Civra A, Feyles E, et al
    Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry.
    Antiviral Res. 2024;226:105897.
    >> Share

  26. AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al
    SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
    Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894.
    >> Share

  27. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
    Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Antiviral Res. 2024;226:105891.
    >> Share

  28. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
    Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
    Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
    >> Share

    March 2024
  29. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
    Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Antiviral Res. 2024;225:105874.
    >> Share

  30. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
    New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
    >> Share

  31. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
    Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
    >> Share

  32. DE MEYER A, Meuleman P
    Preclinical animal models to evaluate therapeutic antiviral antibodies.
    Antiviral Res. 2024 Mar 26:105843. doi: 10.1016/j.antiviral.2024.105843.
    >> Share

  33. MOON C, Porges E, Roberts A, Bacon J, et al
    A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
    Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
    >> Share

  34. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
    SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
    Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
    >> Share

  35. WANG W, Wang S, Meng X, Zhao Y, et al
    A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
    Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
    >> Share

  36. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
    Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
    Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
    >> Share

  37. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
    The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
    Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
    >> Share

    February 2024
  38. NOBORI H, Baba K, Kuroda T, Baba K, et al
    Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Antiviral Res. 2024;224:105852.
    >> Share

  39. LI H, Sun M, Lei F, Liu J, et al
    Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3?C?L protease as a potential candidate against SARS-cov-2 infection.
    Antiviral Res. 2024 Feb 24:105841. doi: 10.1016/j.antiviral.2024.105841.
    >> Share

  40. BIGOTTI MG, Klein K, Gan ES, Anastasina M, et al
    The alpha-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses.
    Antiviral Res. 2024 Feb 20:105837. doi: 10.1016/j.antiviral.2024.105837.
    >> Share

  41. SANTOS-FERREIRA N, Van Dycke J, Chiu W, Neyts J, et al
    Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
    Antiviral Res. 2024;223:105839.
    >> Share

  42. TAM EH, Peng Y, Yan Cheah MX, Yan C, et al
    Neutralizing antibodies to block viral entry and for identification of entry inhibitors.
    Antiviral Res. 2024 Feb 16:105834. doi: 10.1016/j.antiviral.2024.105834.
    >> Share

  43. SINHA D, Yaugel-Novoa M, Waeckel L, Paul S, et al
    Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses.
    Antiviral Res. 2024 Feb 6:105823. doi: 10.1016/j.antiviral.2024.105823.
    >> Share

  44. WANG Y, Liu Y, Wang J, Zhang M, et al
    An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses.
    Antiviral Res. 2024;223:105825.
    >> Share

  45. JIAO Z, Wang P, Hu X, Chen Y, et al
    Feline infectious peritonitis virus ORF7a is a virulence factor involved in inflammatory pathology in cats.
    Antiviral Res. 2024;222:105794.
    >> Share

    January 2024
  46. WINIGER RR, Perez L
    Therapeutic antibodies and alternative formats against SARS-CoV-2.
    Antiviral Res. 2024 Jan 31:105820. doi: 10.1016/j.antiviral.2024.105820.
    >> Share

  47. BOUZIDI HS, Driouich JS, Klitting R, Bernadin O, et al
    Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
    Antiviral Res. 2024 Jan 23:105814. doi: 10.1016/j.antiviral.2024.105814.
    >> Share

  48. BOGACHEVA MS, Kuivanen S, Potdar S, Hassinen A, et al
    Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
    Antiviral Res. 2024 Jan 23:105813. doi: 10.1016/j.antiviral.2024.105813.
    >> Share

  49. BOND ACS, Crocker MA, Wilczek MP, DuShane JK, et al
    High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection.
    Antiviral Res. 2024 Jan 19:105817. doi: 10.1016/j.antiviral.2024.105817.
    >> Share

  50. IDRIS A, Supramaniam A, Tayyar Y, Kelly G, et al
    An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.
    Antiviral Res. 2024;222:105815.
    >> Share

  51. GOVEDNIK T, Lainscek D, Kuhar U, Lachish M, et al
    TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences.
    Antiviral Res. 2024 Jan 9:105806. doi: 10.1016/j.antiviral.2024.105806.
    >> Share

  52. GARCIA-RODRIGUEZ I, Moreni G, Capendale PE, Mulder L, et al
    Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.
    Antiviral Res. 2024 Jan 6:105798. doi: 10.1016/j.antiviral.2024.105798.
    >> Share

    December 2023
  53. CHEN X, Tian L, Zhang L, Gao W, et al
    Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein.
    Antiviral Res. 2023;221:105790.
    >> Share

  54. DOIJEN J, Heo I, Temmerman K, Vermeulen P, et al
    A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects.
    Antiviral Res. 2023 Dec 27:105789. doi: 10.1016/j.antiviral.2023.105789.
    >> Share

  55. AKSU M, Kumar P, Guttler T, Taxer W, et al
    Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
    Antiviral Res. 2023 Dec 6:105778. doi: 10.1016/j.antiviral.2023.105778.
    >> Share

  56. WANGEN C, Raithel A, Tillmanns J, Gege C, et al
    Validation of nuclear receptor RORgamma isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels.
    Antiviral Res. 2023 Dec 4:105769. doi: 10.1016/j.antiviral.2023.105769.
    >> Share

  57. ZUR M, Peselev T, Yanko S, Rotshild V, et al
    Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
    Antiviral Res. 2023 Dec 4:105768. doi: 10.1016/j.antiviral.2023.105768.
    >> Share

  58. WANG S, Wang Z, Li Y, Tu S, et al
    Generation of whole-porcine neutralizing antibodies of an alphacoronavirus by single B cell antibody technology.
    Antiviral Res. 2023;220:105754.
    >> Share

    November 2023
  59. GALLUCCI L, Bazire J, Davidson AD, Shytaj IL, et al
    Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro.
    Antiviral Res. 2023;221:105766.
    >> Share

  60. WANG S, Cui H, Zhang C, Li W, et al
    Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.
    Antiviral Res. 2023 Nov 28:105765. doi: 10.1016/j.antiviral.2023.105765.
    >> Share

  61. FORRESTALL K, Pringle ES, Sands D, Duguay BA, et al
    A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition.
    Antiviral Res. 2023;220:105758.
    >> Share

  62. SUBRAMANI C, Sharma G, Chaira T, Barman TK, et al
    High content screening strategies for large-scale compound libraries with a focus on high-containment viruses.
    Antiviral Res. 2023 Nov 24:105764. doi: 10.1016/j.antiviral.2023.105764.
    >> Share

  63. GOMEZ-CARBALLA A, Albericio G, Montoto-Louzao J, Perez P, et al
    Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
    Antiviral Res. 2023 Nov 20:105760. doi: 10.1016/j.antiviral.2023.105760.
    >> Share

  64. WU CY, Tseng YC, Kao SE, Wu LY, et al
    Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA(stem)-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses.
    Antiviral Res. 2023 Nov 18:105759. doi: 10.1016/j.antiviral.2023.105759.
    >> Share

  65. ZHANG QY, Zhang HQ, Zhang YN, Zhang ZR, et al
    Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization.
    Antiviral Res. 2023 Nov 18:105757. doi: 10.1016/j.antiviral.2023.105757.
    >> Share

  66. CHUANG YT, Lin YL, Lin JY
    Licochalcone A regulates viral IRES activity to inhibit enterovirus replication.
    Antiviral Res. 2023 Nov 18:105755. doi: 10.1016/j.antiviral.2023.105755.
    >> Share

  67. SADHU S, Dandotiya J, Dalal R, Khatri R, et al
    Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry.
    Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743.
    >> Share

  68. HSIEH HC, Chen CC, Chou PH, Liu WC, et al
    Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
    Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752.
    >> Share

  69. SU WC, Chen ZY, Chang YS, Jeng KS, et al
    Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization.
    Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744.
    >> Share

  70. KIM DG, Kim U, Park IH, Ryu B, et al
    A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants.
    Antiviral Res. 2023 Nov 7:105738. doi: 10.1016/j.antiviral.2023.105738.
    >> Share

    October 2023
  71. DEMIAN WL, Jacob RA, Cormier O, Nazli A, et al
    ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2.
    Antiviral Res. 2023 Oct 18:105736. doi: 10.1016/j.antiviral.2023.105736.
    >> Share

  72. PALLA SR, Li CW, Chao TL, Lo HV, et al
    Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors.
    Antiviral Res. 2023 Oct 17:105735. doi: 10.1016/j.antiviral.2023.105735.
    >> Share

  73. KONKEL R, Milewska A, Do NDT, Barreto Duran E, et al
    Anti-SARS-CoV-2 activity of cyanopeptolins produced by Nostoc edaphicum CCNP1411.
    Antiviral Res. 2023 Oct 12:105731. doi: 10.1016/j.antiviral.2023.105731.
    >> Share

  74. MAMATIS JE, Gallardo-Flores CE, Sangwan U, Tooley TH, et al
    Induction of antiviral gene expression by cyclosporine a, but not inhibition of cyclophilin a or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line.
    Antiviral Res. 2023 Oct 5:105730. doi: 10.1016/j.antiviral.2023.105730.
    >> Share

    September 2023
  75. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
    Corrigendum to ' Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase' [Antiviral Research 218 (2023) 105716-105728/ doi: 10.1016/j.antiviral.2023.105716].
    Antiviral Res. 2023 Sep 28:105729. doi: 10.1016/j.antiviral.2023.105729.
    >> Share

  76. MCMILLAN RE, Lo MK, Zhang XQ, Beadle JR, et al
    Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.
    Antiviral Res. 2023 Sep 25:105718. doi: 10.1016/j.antiviral.2023.105718.
    >> Share

  77. BENNETT RP, Yoluc Y, Salter JD, Ripp A, et al
    Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase.
    Antiviral Res. 2023 Sep 8:105716. doi: 10.1016/j.antiviral.2023.105716.
    >> Share

  78. MARTIN HJ, Melo-Filho CC, Korn D, Eastman RT, et al
    Small molecule antiviral compound collection (SMACC): A comprehensive, highly curated database to support the discovery of broad-spectrum antiviral drug molecules.
    Antiviral Res. 2023;217:105620.
    >> Share

    August 2023
  79. VANDERLINDEN E, Boonen A, Noppen S, Schoofs G, et al
    PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding.
    Antiviral Res. 2023;217:105700.
    >> Share

  80. CORONA A, Madia VN, De Santis R, Manelfi C, et al
    Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication.
    Antiviral Res. 2023;217:105697.
    >> Share

    July 2023
  81. SPENGLER JR, Carter K, Delang L, Durantel D, et al
    Meeting report: 36th international conference on antiviral research in Lyon, France, March 13-17, 2023.
    Antiviral Res. 2023 Jul 24:105678. doi: 10.1016/j.antiviral.2023.105678.
    >> Share

  82. SUPREWICZ L, Szczepanski A, Lenart M, Piktel E, et al
    Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response.
    Antiviral Res. 2023 Jul 20:105676. doi: 10.1016/j.antiviral.2023.105676.
    >> Share

  83. BOWDEN-REID E, Ledger S, Zhang Y, Di Giallonardo F, et al
    Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
    Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677.
    >> Share

  84. LI Y, Wang Y, Li Y, de Vries AC, et al
    Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable.
    Antiviral Res. 2023 Jul 15:105674. doi: 10.1016/j.antiviral.2023.105674.
    >> Share

  85. TAKASHITA E, Fujisaki S, Morita H, Nagata S, et al
    Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Antiviral Res. 2023;216:105671.
    >> Share

  86. JEONG JH, Choi JH, Kim BK, Min SC, et al
    Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses.
    Antiviral Res. 2023 Jul 10:105669. doi: 10.1016/j.antiviral.2023.105669.
    >> Share

  87. FENG Y, Yang Y, Zou S, Qiu S, et al
    Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
    Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
    >> Share

    June 2023
  88. CAI H, Yan J, Liu S, Li P, et al
    Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.
    Antiviral Res. 2023 Jun 25:105659. doi: 10.1016/j.antiviral.2023.105659.
    >> Share

  89. MILAN BONOTTO R, Mitrovic A, Sosic I, Martinez-Orellana P, et al
    Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection.
    Antiviral Res. 2023;216:105655.
    >> Share

  90. JUNG HE, Ku KB, Kang BH, Park JH, et al
    Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Antiviral Res. 2023;216:105656.
    >> Share

  91. CHANG YJ, Le UNP, Liu JJ, Li SR, et al
    Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Antiviral Res. 2023 Jun 13:105653. doi: 10.1016/j.antiviral.2023.105653.
    >> Share

    May 2023
  92. DRIOUICH JS, Bernadin O, Touret F, de Lamballerie X, et al
    Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
    Antiviral Res. 2023 May 17:105638. doi: 10.1016/j.antiviral.2023.105638.
    >> Share

  93. HUANG X, Fan W, Sun J, Yang J, et al
    SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
    Antiviral Res. 2023 May 17:105636. doi: 10.1016/j.antiviral.2023.105636.
    >> Share

    April 2023
  94. CHO J, Shin Y, Yang JS, Kim JW, et al
    Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Antiviral Res. 2023;214:105609.
    >> Share

  95. LI Y, Wang K, Sun H, Wu S, et al
    Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
    Antiviral Res. 2023 Apr 17:105606. doi: 10.1016/j.antiviral.2023.105606.
    >> Share

  96. CONG Y, Lee JH, Perry DL, Cooper K, et al
    Longitudinal analyses using (18)F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
    Antiviral Res. 2023 Apr 15:105605. doi: 10.1016/j.antiviral.2023.105605.
    >> Share

    March 2023
  97. BILLS C, Xie X, Shi PY
    The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2.
    Antiviral Res. 2023;213:105590.
    >> Share

  98. CONG Y, Mucker EM, Perry DL, Dixit S, et al
    Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
    Antiviral Res. 2023;213:105589.
    >> Share

  99. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
    Corrigendum to "Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics" "Antiviral Research 209 (2023)/105484".
    Antiviral Res. 2023 Mar 30:105577. doi: 10.1016/j.antiviral.2023.105577.
    >> Share

  100. YANG Y, Cao L, Yan M, Zhou J, et al
    Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Antiviral Res. 2023 Mar 28:105586. doi: 10.1016/j.antiviral.2023.105586.
    >> Share

  101. VANHULLE E, Doijen J, Stroobants J, Provinciael B, et al
    Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants.
    Antiviral Res. 2023;213:105587.
    >> Share

  102. DICHTL S, Diem G, Jager M, Zaderer V, et al
    Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation.
    Antiviral Res. 2023 Mar 23:105581. doi: 10.1016/j.antiviral.2023.105581.
    >> Share

  103. ALVES RPDS, Wang YT, Mikulski Z, McArdle S, et al
    SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model.
    Antiviral Res. 2023 Mar 18:105580. doi: 10.1016/j.antiviral.2023.105580.
    >> Share

  104. LIANG JQ, Xie MY, Hou L, Wang HL, et al
    miRNAs derived from milk small extracellular vesicles inhibit porcine epidemic diarrhea virus infection.
    Antiviral Res. 2023 Mar 10:105579. doi: 10.1016/j.antiviral.2023.105579.
    >> Share

  105. LU C, Zhang Y, Liu X, Hou F, et al
    Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine.
    Antiviral Res. 2023;212:105556.
    >> Share

  106. KIM JW, Heo K, Kim HJ, Yoo Y, et al
    Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.
    Antiviral Res. 2023;212:105576.
    >> Share

  107. SHEKUNOV EV, Zlodeeva PD, Efimova SS, Muryleva AA, et al
    Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs.
    Antiviral Res. 2023;212:105575.
    >> Share

  108. HU Y, Zhu Y, Yu Y, Liu N, et al
    Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Antiviral Res. 2023;212:105571.
    >> Share

    February 2023
  109. ZHAO L, Yao L, Chen R, He J, et al
    Pinosrtobin from plants and propolis against human coronavirus HCoV-OC43 by modulating host AHR/CYP1A1 pathway and lipid metabolism.
    Antiviral Res. 2023 Feb 28:105570. doi: 10.1016/j.antiviral.2023.105570.
    >> Share

  110. XIAO Y, Yan Y, Chang L, Ji H, et al
    CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation.
    Antiviral Res. 2023 Feb 18:105558. doi: 10.1016/j.antiviral.2023.105558.
    >> Share

  111. LI J, Wang Y, Solanki K, Atre R, et al
    Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses.
    Antiviral Res. 2023 Feb 13:105555. doi: 10.1016/j.antiviral.2023.105555.
    >> Share

  112. MERINO VF, Yan Y, Ordonez AA, Bullen CK, et al
    Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells.
    Antiviral Res. 2023;211:105550.
    >> Share

  113. KURHADE C, Xie X, Shi PY
    Reverse genetic systems of SARS-CoV-2 for antiviral research.
    Antiviral Res. 2023;210:105486.
    >> Share

    January 2023
  114. ZHU Y, Li M, Liu N, Wu T, et al
    Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.
    Antiviral Res. 2023;211:105541.
    >> Share

  115. BASILE A, Zannella C, De Marco M, Sanna G, et al
    Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody.
    Antiviral Res. 2023;211:105546.
    >> Share

    December 2022
  116. SPENGLER JR, Welch SR, Deval J, Gentry BG, et al
    Meeting report: 35th international conference on antiviral research in Seattle, WA, USA - March 21-25, 2022.
    Antiviral Res. 2022 Dec 31:105521. doi: 10.1016/j.antiviral.2022.105521.
    >> Share

  117. CHISTOV AA, Chumakov SP, Mikhnovets IE, Nikitin TD, et al
    5-(Perylen-3-ylethynyl)uracil as an antiviral scaffold: Potent suppression of enveloped virus reproduction by 3-methyl derivatives in vitro.
    Antiviral Res. 2022 Dec 26:105508. doi: 10.1016/j.antiviral.2022.105508.
    >> Share

  118. LIM SP
    Targeting SARS-CoV-2 and host cell receptor interactions.
    Antiviral Res. 2022 Dec 26:105514. doi: 10.1016/j.antiviral.2022.105514.
    >> Share

  119. HU L, Tang Y, Mei L, Liang M, et al
    A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly.
    Antiviral Res. 2022;209:105509.
    >> Share

  120. TNG DJH, Low JGH
    Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.
    Antiviral Res. 2022 Dec 22:105488. doi: 10.1016/j.antiviral.2022.105488.
    >> Share

  121. SHANNON A, Canard B
    Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.
    Antiviral Res. 2022 Dec 21:105501. doi: 10.1016/j.antiviral.2022.105501.
    >> Share

  122. CHIU W, Schepers J, Francken T, Vangeel L, et al
    Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
    Antiviral Res. 2022 Dec 21:105506. doi: 10.1016/j.antiviral.2022.105506.
    >> Share

  123. ZHANG YN, Zhang HQ, Wang GF, Zhang ZR, et al
    Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster.
    Antiviral Res. 2022;209:105507.
    >> Share

  124. JOHNSON DM, Brasel T, Massey S, Garron T, et al
    Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Antiviral Res. 2022 Dec 16:105492. doi: 10.1016/j.antiviral.2022.105492.
    >> Share

  125. PEREZ-VARGAS J, Shapira T, Olmstead AD, Villanueva I, et al
    Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
    Antiviral Res. 2022 Dec 8:105484. doi: 10.1016/j.antiviral.2022.105484.
    >> Share

  126. HASHIZUME M, Takashima A, Ono C, Okamoto T, et al
    Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
    Antiviral Res. 2022 Dec 5:105481. doi: 10.1016/j.antiviral.2022.105481.
    >> Share

  127. YAO Y, Sun H, Chen Y, Tian L, et al
    RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region.
    Antiviral Res. 2022;209:105478.
    >> Share

    November 2022
  128. JEONG K, Chang J, Park SM, Kim J, et al
    Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay.
    Antiviral Res. 2022 Nov 23:105473. doi: 10.1016/j.antiviral.2022.105473.
    >> Share

  129. FAIST A, Schloer S, Mecate-Zambrano A, Janowski J, et al
    Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier.
    Antiviral Res. 2022 Nov 21:105475. doi: 10.1016/j.antiviral.2022.105475.
    >> Share

  130. HUI X, Yu X, Huang K, Xu T, et al
    In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection.
    Antiviral Res. 2022 Nov 16:105465. doi: 10.1016/j.antiviral.2022.105465.
    >> Share

  131. FABREGA-FERRER M, Herrera-Morande A, Muriel-Goni S, Perez-Saavedra J, et al
    Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
    Antiviral Res. 2022;208:105458.
    >> Share

  132. ZENG Y, Song F, Luo G, Yang H, et al
    Generation and characterization of mouse monoclonal antibodies against the VP4 protein of group A human rotaviruses.
    Antiviral Res. 2022;207:105407.
    >> Share

    October 2022
  133. ZHANG T, Su S, Altouma V, Zhu X, et al
    Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus.
    Antiviral Res. 2022 Oct 31:105451. doi: 10.1016/j.antiviral.2022.105451.
    >> Share

  134. VARRICCHIO C, Mathez G, Pillonel T, Bertelli C, et al
    Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting.
    Antiviral Res. 2022;208:105452.
    >> Share

  135. SHANG W, Dai W, Yao C, Xu L, et al
    In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2.
    Antiviral Res. 2022;208:105450.
    >> Share

  136. ZHU Y, Hu Y, Liu N, Chong H, et al
    Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Antiviral Res. 2022;208:105445.
    >> Share

  137. KIM TY, Kim JY, Kwon HC, Jeon S, et al
    Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibit the infection of SARS-CoV-2 variants and syncytium formation.
    Antiviral Res. 2022 Oct 14:105428. doi: 10.1016/j.antiviral.2022.105428.
    >> Share

  138. BRAY M
    Antiviral Research: At age 41, a transition.
    Antiviral Res. 2022 Oct 14:105447. doi: 10.1016/j.antiviral.2022.105447.
    >> Share

  139. JEONG JH, Chokkakula S, Min SC, Kim BK, et al
    Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
    Antiviral Res. 2022;208:105430.
    >> Share

  140. ZHU Y, Binder J, Yurgelonis I, Rai D, et al
    Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study.
    Antiviral Res. 2022 Oct 5:105429. doi: 10.1016/j.antiviral.2022.105429.
    >> Share

    September 2022
  141. MA L, Li Q, Xie Y, Jianyuan Zhao, et al
    Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro).
    Antiviral Res. 2022 Sep 22:105419. doi: 10.1016/j.antiviral.2022.105419.
    >> Share

    August 2022
  142. DEMAREST JF, Kienle M, Boytz R, Ayres M, et al
    Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19.
    Antiviral Res. 2022 Aug 27:105403. doi: 10.1016/j.antiviral.2022.105403.
    >> Share

  143. LAI M, De Carli A, Filipponi C, Iacono E, et al
    Lipid balance remodelling by human positive-strand RNA viruses and the contribution of lysosomes.
    Antiviral Res. 2022 Aug 17:105398. doi: 10.1016/j.antiviral.2022.105398.
    >> Share

  144. LU L, Peng Y, Yao H, Wang Y, et al
    Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro.
    Antiviral Res. 2022 Aug 16:105389. doi: 10.1016/j.antiviral.2022.105389.
    >> Share

    July 2022
  145. LI M, Chen J, Liu Y, Zhao J, et al
    Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
    Antiviral Res. 2022 Jul 30:105383. doi: 10.1016/j.antiviral.2022.105383.
    >> Share

  146. SAMRAT SK, Xu J, Xie X, Gianti E, et al
    Allosteric inhibitors of the main protease of SARS-CoV-2.
    Antiviral Res. 2022;205:105381.
    >> Share

  147. BEZERRA BB, Silva GPDD, Antunes Coelho SV, Correa IA, et al
    Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines.
    Antiviral Res. 2022 Jul 4:105373. doi: 10.1016/j.antiviral.2022.105373.
    >> Share

  148. OHASHI H, Hishiki T, Akazawa D, Kim KS, et al
    Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
    Antiviral Res. 2022 Jul 4:105372. doi: 10.1016/j.antiviral.2022.105372.
    >> Share

    June 2022
  149. KIM EH, Lee BW, Ryu B, Cho HM, et al
    Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice.
    Antiviral Res. 2022;204:105371.
    >> Share

  150. SEEPHETDEE C, Bhukhai K, Buasri N, Leelukkanaveera P, et al
    A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
    Antiviral Res. 2022 Jun 27:105370. doi: 10.1016/j.antiviral.2022.105370.
    >> Share

  151. KARIM M, Saul S, Ghita L, Sahoo MK, et al
    Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies.
    Antiviral Res. 2022 Jun 20:105367. doi: 10.1016/j.antiviral.2022.105367.
    >> Share

  152. ZHOU M, Liu Y, Cao J, Dong S, et al
    Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters.
    Antiviral Res. 2022 Jun 19:105365. doi: 10.1016/j.antiviral.2022.105365.
    >> Share

  153. HERNANDEZ S, Feracci M, De Jesus CT, El Kazzi P, et al
    Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.
    Antiviral Res. 2022 Jun 15:105364. doi: 10.1016/j.antiviral.2022.105364.
    >> Share

  154. MELO-FILHO CC, Bobrowski T, Martin HJ, Sessions Z, et al
    Conserved coronavirus proteins as targets of broad-spectrum antivirals.
    Antiviral Res. 2022 Jun 9:105360. doi: 10.1016/j.antiviral.2022.105360.
    >> Share

  155. MERCORELLI B, Desantis J, Celegato M, Bazzacco A, et al
    Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization.
    Antiviral Res. 2022;204:105350.
    >> Share

    May 2022
  156. PRASHAR P, Swain S, Adhikari N, Aryan P, et al
    A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.
    Antiviral Res. 2022 May 28:105349. doi: 10.1016/j.antiviral.2022.105349.
    >> Share

  157. LIN Q, Lu C, Hong Y, Li R, et al
    Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
    Antiviral Res. 2022 May 20:105345. doi: 10.1016/j.antiviral.2022.105345.
    >> Share

  158. ROY A, Alhammad YM, McDonald P, Johnson DK, et al
    Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Antiviral Res. 2022 May 19:105344. doi: 10.1016/j.antiviral.2022.105344.
    >> Share

  159. WEIL T, Lawrenz J, Seidel A, Munch J, et al
    Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
    Antiviral Res. 2022 May 19:105343. doi: 10.1016/j.antiviral.2022.105343.
    >> Share

  160. VANHULLE E, Stroobants J, Provinciael B, Camps A, et al
    SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
    Antiviral Res. 2022 May 17:105342. doi: 10.1016/j.antiviral.2022.105342.
    >> Share

  161. FINDLAY-WILSON S, Easterbrook L, Smith S, Pope N, et al
    Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
    Antiviral Res. 2022 May 6:105332. doi: 10.1016/j.antiviral.2022.105332.
    >> Share

  162. PITTS J, Babusis D, Vermillion MS, Subramanian R, et al
    Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
    Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329.
    >> Share

    April 2022
  163. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
    HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
    Antiviral Res. 2022;202:105311.
    >> Share

  164. VANMECHELEN B, Stroobants J, Chiu W, Schepers J, et al
    Identification of novel Ebola virus inhibitors using biologically contained virus.
    Antiviral Res. 2022;200:105294.
    >> Share

    March 2022
  165. UENO M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, et al
    Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
    Antiviral Res. 2022;201:105297.
    >> Share

  166. LAI GC, Chao TL, Lin SY, Kao HC, et al
    Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
    Antiviral Res. 2022;200:105290.
    >> Share

  167. PASQUERO S, Gugliesi F, Griffante G, Dell'Oste V, et al
    Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
    Antiviral Res. 2022;200:105278.
    >> Share

  168. CHEN KY, Krischuns T, Varga LO, Harigua-Souiai E, et al
    A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Antiviral Res. 2022 Mar 9:105272. doi: 10.1016/j.antiviral.2022.105272.
    >> Share

  169. SCHOLLE MD, O'Kane PT, Dib S, Gurard-Levin ZA, et al
    Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
    Antiviral Res. 2022;200:105279.
    >> Share

  170. TANAKA T, Saito A, Suzuki T, Miyamoto Y, et al
    Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening.
    Antiviral Res. 2022;199:105268.
    >> Share

    February 2022
  171. TSAI TI, Khalili JS, Gilchrist M, Waight AB, et al
    ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern.
    Antiviral Res. 2022 Feb 28:105271. doi: 10.1016/j.antiviral.2022.105271.
    >> Share

  172. SACHSE M, Tenorio R, Fernandez de Castro I, Munoz-Basagoiti J, et al
    Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis.
    Antiviral Res. 2022 Feb 26:105270. doi: 10.1016/j.antiviral.2022.105270.
    >> Share

    January 2022
  173. ZHAO J, Liu Q, Yi D, Li Q, et al
    5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
    Antiviral Res. 2022 Jan 28:105254. doi: 10.1016/j.antiviral.2022.105254.
    >> Share

  174. VANGEEL L, Chiu W, De Jonghe S, Maes P, et al
    Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
    Antiviral Res. 2022 Jan 24:105252. doi: 10.1016/j.antiviral.2022.105252.
    >> Share

  175. ABDELNABI R, Foo CS, Zhang X, Lemmens V, et al
    The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
    Antiviral Res. 2022 Jan 20:105253. doi: 10.1016/j.antiviral.2022.105253.
    >> Share

  176. FOCOSI D, Maggi F, McConnell S, Casadevall A, et al
    Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
    Antiviral Res. 2022;198:105247.
    >> Share

  177. WILLIAMSON BN, Perez-Perez L, Schwarz B, Feldmann F, et al
    Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.
    Antiviral Res. 2022 Jan 12:105246. doi: 10.1016/j.antiviral.2022.105246.
    >> Share

    December 2021
  178. KUMAR R, Khandelwal N, Chander Y, Nagori H, et al
    S-adenosylmethionine-dependent methyltransferase inhibitor DZNep blocks transcription and translation of SARS-CoV-2 genome with a low tendency to select for drug-resistant viral variants.
    Antiviral Res. 2021 Dec 27:105232. doi: 10.1016/j.antiviral.2021.105232.
    >> Share

  179. MCKIMM-BRESCHKIN JL, Hay AJ, Cao B, Cox RJ, et al
    COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference.
    Antiviral Res. 2021 Dec 18:105227. doi: 10.1016/j.antiviral.2021.105227.
    >> Share

    November 2021
  180. COCHIN M, Touret F, Driouich JS, Moureau G, et al
    Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
    Antiviral Res. 2021;197:105212.
    >> Share

  181. ZHAO J, Zhang G, Zhang Y, Yi D, et al
    2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
    Antiviral Res. 2021;196:105209.
    >> Share

  182. SVILENOV HL, Sacherl J, Reiter A, Wolff LS, et al
    Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
    Antiviral Res. 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.
    >> Share

  183. QIU H, Yuan XY, Cabral T, Manguiat K, et al
    Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
    Antiviral Res. 2021 Nov 8:105206. doi: 10.1016/j.antiviral.2021.105206.
    >> Share

    October 2021
  184. WANG YT, Allen RD 3rd, Kim K, Shafee N, et al
    SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
    Antiviral Res. 2021 Oct 8:105185. doi: 10.1016/j.antiviral.2021.105185.
    >> Share

  185. DEY-RAO R, Smith GR, Timilsina U, Falls Z, et al
    A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition.
    Antiviral Res. 2021;195:105183.
    >> Share

    September 2021
  186. JULANDER JG, Demarest JF, Taylor R, Gowen BB, et al
    An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
    Antiviral Res. 2021 Sep 19:105180. doi: 10.1016/j.antiviral.2021.105180.
    >> Share

    August 2021
  187. GARCIA-DORIVAL I, Cuesta-Geijo MA, Barrado-Gil L, Galindo I, et al
    Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target.
    Antiviral Res. 2021 Aug 24:105167. doi: 10.1016/j.antiviral.2021.105167.
    >> Share

  188. ESCAFFRE O, Freiberg AN
    Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells.
    Antiviral Res. 2021 Aug 9:105162. doi: 10.1016/j.antiviral.2021.105162.
    >> Share

  189. LEACH A, Ilca FT, Akbar Z, Ferrari M, et al
    A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Antiviral Res. 2021 Aug 7:105147. doi: 10.1016/j.antiviral.2021.105147.
    >> Share

  190. ISON MG, Hayden FG, Hay AJ, Gubareva LV, et al
    Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
    Antiviral Res. 2021;194:105158.
    >> Share

    July 2021
  191. KASPRZYK R, Spiewla TJ, Smietanski M, Golojuch S, et al
    Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
    Antiviral Res. 2021;193:105142.
    >> Share

  192. TOURET F, Driouich JS, Cochin M, Petit PR, et al
    Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
    Antiviral Res. 2021;193:105137.
    >> Share

  193. GAN ES, Syenina A, Linster M, Ng B, et al
    A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
    Antiviral Res. 2021;193:105138.
    >> Share

  194. PERSOONS L, Vanderlinden E, Vangeel L, Wang X, et al
    Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
    Antiviral Res. 2021 Jul 1:105127. doi: 10.1016/j.antiviral.2021.105127.
    >> Share

    June 2021
  195. DO TND, Donckers K, Vangeel L, Chatterjee AK, et al
    A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
    Antiviral Res. 2021 Jun 26:105122. doi: 10.1016/j.antiviral.2021.105122.
    >> Share

  196. KASHYAP T, Murray J, Walker CJ, Chang H, et al
    Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
    Antiviral Res. 2021 Jun 19:105115. doi: 10.1016/j.antiviral.2021.105115.
    >> Share

    May 2021
  197. PAULL JRA, Heery GP, Bobardt MD, Castellarnau A, et al
    Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.
    Antiviral Res. 2021 May 16:105089. doi: 10.1016/j.antiviral.2021.105089.
    >> Share

    April 2021
  198. ZHAO J, Guo S, Yi D, Li Q, et al
    A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Antiviral Res. 2021;190:105078.
    >> Share

  199. DU R, Cooper L, Chen Z, Lee H, et al
    Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CL(pro).
    Antiviral Res. 2021 Apr 16:105075. doi: 10.1016/j.antiviral.2021.105075.
    >> Share

    March 2021
  200. CICCOSANTI F, Di Rienzo M, Romagnoli A, Colavita F, et al
    Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.
    Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064.
    >> Share

  201. MILANI M, Donalisio M, Bonotto RM, Schneider E, et al
    Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
    Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055.
    >> Share

  202. KUMAR R, Afsar M, Khandelwal N, Chander Y, et al
    Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.
    Antiviral Res. 2021 Mar 9:105056. doi: 10.1016/j.antiviral.2021.105056.
    >> Share

    February 2021
  203. MARTIN R, Li J, Parvangada A, Perry J, et al
    Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
    Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
    >> Share

    January 2021
  204. LIU C, Boland S, Scholle MD, Bardiot D, et al
    Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.
    Antiviral Res. 2021 Jan 27:105020. doi: 10.1016/j.antiviral.2021.105020.
    >> Share

  205. ZHU Q, Zhang Y, Wang L, Yao X, et al
    Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Antiviral Res. 2021 Jan 11:105015. doi: 10.1016/j.antiviral.2021.105015.
    >> Share

  206. MULLER C, Obermann W, Karl N, Wendel HG, et al
    The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
    Antiviral Res. 2021;186:105012.
    >> Share

    December 2020
  207. SUN X, Li L, Pan L, Wang Z, et al
    Infectious bronchitis virus: Identification of Gallus gallus APN high-affinity ligands with antiviral effects.
    Antiviral Res. 2020 Dec 16:104998. doi: 10.1016/j.antiviral.2020.104998.
    >> Share

  208. GAN HJ, Harikishore A, Lee J, Jeon S, et al
    Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.
    Antiviral Res. 2020;185:104996.
    >> Share

    November 2020
  209. GALINDO I, Garaigorta U, Lasala F, Cuesta-Geijo MA, et al
    Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses.
    Antiviral Res. 2020 Nov 26:104990. doi: 10.1016/j.antiviral.2020.104990.
    >> Share

  210. SVENNINGSEN EB, Thyrsted J, Blay-Cadanet J, Liu H, et al
    Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
    Antiviral Res. 2020 Nov 25:104988. doi: 10.1016/j.antiviral.2020.104988.
    >> Share

  211. ZHANG Y, Song W, Chen S, Yuan Z, et al
    A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
    Antiviral Res. 2020 Nov 17:104974. doi: 10.1016/j.antiviral.2020.104974.
    >> Share

    October 2020
  212. CHOI SW, Shin JS, Park SJ, Jung E, et al
    Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Antiviral Res. 2020 Oct 19:104955. doi: 10.1016/j.antiviral.2020.104955.
    >> Share

    September 2020
  213. THEERAWATANASIRIKUL S, Kuo CJ, Phecharat N, Chootip J, et al
    Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Antiviral Res. 2020 Sep 7:104927. doi: 10.1016/j.antiviral.2020.104927.
    >> Share

  214. GURARD-LEVIN ZA, Liu C, Jekle A, Jaisinghani R, et al
    Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Antiviral Res. 2020 Sep 4:104924. doi: 10.1016/j.antiviral.2020.104924.
    >> Share

    August 2020
  215. KONKOLOVA E, Dejmek M, Hrebabecky H, Sala M, et al
    Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
    Antiviral Res. 2020 Aug 4:104899. doi: 10.1016/j.antiviral.2020.104899.
    >> Share

  216. JEON YJ, Gil CH, Jo A, Won J, et al
    The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium.
    Antiviral Res. 2020;180:104860.
    >> Share

    July 2020
  217. OKAMOTO M, Toyama M, Baba M
    The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 30:104902. doi: 10.1016/j.antiviral.2020.104902.
    >> Share

  218. CONZELMANN C, Gilg A, Gross R, Schutz D, et al
    An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
    Antiviral Res. 2020 Jul 29:104882. doi: 10.1016/j.antiviral.2020.104882.
    >> Share

  219. PRASANTH KR, Hirano M, Fagg WS, McAnarney ET, et al
    Topoisomerase III-ss is required for efficient replication of positive-sense RNA viruses.
    Antiviral Res. 2020 Jul 28:104874. doi: 10.1016/j.antiviral.2020.104874.
    >> Share

  220. GALLIAN P, Pastorino B, Morel P, Chiaroni J, et al
    Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
    Antiviral Res. 2020 Jul 14:104880. doi: 10.1016/j.antiviral.2020.104880.
    >> Share

  221. PIZZORNO A, Padey B, Dubois J, Julien T, et al
    In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
    Antiviral Res. 2020 Jul 14:104878. doi: 10.1016/j.antiviral.2020.104878.
    >> Share

  222. VENISSE N, Peytavin G, Bouchet S, Gagnieu MC, et al
    Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
    Antiviral Res. 2020 Jul 10:104866. doi: 10.1016/j.antiviral.2020.104866.
    >> Share

  223. PAN X, Zhou P, Fan T, Wu Y, et al
    Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868.
    >> Share

  224. KIM SY, Jin W, Sood A, Montgomery DW, et al
    Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
    Antiviral Res. 2020 Jul 9:104873. doi: 10.1016/j.antiviral.2020.104873.
    >> Share

    June 2020
  225. JOCKUSCH S, Tao C, Li X, Anderson TK, et al
    A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
    Antiviral Res. 2020;180:104857.
    >> Share

  226. SHANNON A, Le NT, Selisko B, Eydoux C, et al
    Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
    Antiviral Res. 2020;178:104793.
    >> Share

    May 2020
  227. TAI W, Zhang X, He Y, Jiang S, et al
    Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Antiviral Res. 2020 May 13:104820. doi: 10.1016/j.antiviral.2020.104820.
    >> Share

    April 2020
  228. MANTLO E, Bukreyeva N, Maruyama J, Paessler S, et al
    Antiviral activities of type I interferons to SARS-CoV-2 infection.
    Antiviral Res. 2020;179:104811.
    >> Share

  229. BRAY M, Rayner C, Noel F, Jans D, et al
    Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.
    Antiviral Res. 2020 Apr 21:104805. doi: 10.1016/j.antiviral.2020.104805.
    >> Share

  230. SALLARD E, Lescure FX, Yazdanpanah Y, Mentre F, et al
    Type 1 interferons as a potential treatment against COVID-19.
    Antiviral Res. 2020;178:104791.
    >> Share

  231. TANG T, Bidon M, Jaimes JA, Whittaker GR, et al
    Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.
    Antiviral Res. 2020 Apr 6:104792. doi: 10.1016/j.antiviral.2020.104792.
    >> Share

  232. CALY L, Druce JD, Catton MG, Jans DA, et al
    The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Apr 3:104787. doi: 10.1016/j.antiviral.2020.104787.
    >> Share

  233. CHOY KT, Yin-Lam Wong A, Kaewpreedee P, Sia SF, et al
    Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Antiviral Res. 2020 Apr 3:104786. doi: 10.1016/j.antiviral.2020.104786.
    >> Share

    March 2020
  234. TOURET F, de Lamballerie X
    Of chloroquine and COVID-19.
    Antiviral Res. 2020;177:104762.
    >> Share

  235. SIGRIST C, Bridge A, Le Mercier P
    A potential role for integrins in host cell entry by SARS-CoV-2.
    Antiviral Res. 2020 Mar 1:104759. doi: 10.1016/j.antiviral.2020.104759.
    >> Share

    February 2020
  236. COUTARD B, Valle C, de Lamballerie X, Canard B, et al
    The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.
    Antiviral Res. 2020;176:104742.
    >> Share

  237. CLASMAN JR, Everett RK, Srinivasan K, Mesecar AD, et al
    Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease.
    Antiviral Res. 2020;174:104661.
    >> Share

    January 2020
  238. NIU J, Shen L, Huang B, Ye F, et al
    Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice.
    Antiviral Res. 2020;173:104646.
    >> Share

  239. MA-LAUER Y, Zheng Y, Malesevic M, von Brunn B, et al
    Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication.
    Antiviral Res. 2020;173:104620.
    >> Share

    December 2019
  240. THEERAWATANASIRIKUL S, Kuo CJ, Phetcharat N, Lekcharoensuk P, et al
    In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus.
    Antiviral Res. 2019;174:104697.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016